Table 3 Adverse events and complications of the two treatment groups.
One-stage | Two-stage | P-value | |
|---|---|---|---|
Injury of neighboring structures | 0 (0%) | 0 (0%) | > 0.99 |
Night-vision-symptoms | |||
Glare | 0 (0%) | 0 (0%) | > 0.99 |
Halos | 4 (4%) | 4 (5.1%) | 0.73 |
Starburst | 0 (0%) | 1 (1%) | 0.44 |
Abnormal ICL-position | |||
ICL-dislocation | 0 (0%) | 0 (0%) | > 0.99 |
ICL-rotation | 1 (1%) | 1 (1.3%) | > 0.99 |
ICL-inversion | 0 (0%) | 0 (0%) | > 0.99 |
Endothelial cell number loss cells/mm2 | 1.3 % | 4.3 % | 0.016 |
Increased intraocular pressure | 2 (4%) | 1 (1.3%) | > 0.99 |
Endophthalmitis | 0 (0%) | 0 (0%) | > 0.99 |
Cataract | 0 (0%) | 0 (0%) | > 0.99 |
Macular edema | 4 (4%) | 3 (3.8%) | > 0.99 |
